98 Results for "

Immune Checkpoints

" in MedChemExpress (MCE) Product Catalog:
Products (98)

98 Results for "Immune Checkpoints" in MCE Product Catalog:

Cat. No.: HY-143305
CAS No.: 2768759-52-8
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of PD-1/PD-L1 interaction with an IC50 value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-179228
CAS No.: 1246964-08-8
Target:  

CTLA-4 TGF-beta/Smad

Research Areas:  

Cancer

AN02 is a derivative of Curcumin (HY-N0005). AN02 inhibits the proliferation and clonogenicity, migration and invasion of ovarian cancer cells. AN02 dose-dependently upregulates the expression of APC and mediates the degradation of CTLA-4 through SMAD4. In the small xenograft model, AN02 significantly inhibits tumor growth and reverses the tumor immune-suppressive microenvironment. AN02, when combined with Ipilimumab (HY-P9901), can enhance efficacy and inhibit epithelial-mesenchymal transition. AN02 can be used for the study of ovarian cancer .
loading...
    loading...
Cat. No.: HY-162810
CAS No.: 1006002-58-9
Target:  

CD28

Research Areas:  

Others

ICOS-IN-1 (compound 9) is an inhibitor of the interaction between ICOS and ICOS-L (IC50=29.38 μM) and has activity in recognizing immune checkpoints .
loading...
    loading...
Cat. No.: HY-124615
CAS No.: 1883817-83-1
Target:  

p38 MAPK PI3K

Research Areas:  

Cancer

ST-162 is a MAPK/PI3K dual antagonist. ST-162 exhibits antitumor activity and can increase the efficacy of immune checkpoint blockers. ST-162 can be used for the research of cancer, such as melanoma .
loading...
    loading...
Cat. No.: HY-174460
Target:  

Drug Intermediate

Research Areas:  

Cancer

pCR8 is a CR8 prodrug and anticancer agent responsive to H2O2. pCR8 achieves selective release of CR8 via boronate ester oxidation mediated by elevated hydrogen peroxide levels at tumor sites, self-assembles into nanoparticles, and degrades cell cycle-related proteins. A synergistic effect is produced when pCR8 is used in combination with immune checkpoint inhibitors. pCR8 can be used for the research of triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-P10715
Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research .
loading...
    loading...
Cat. No.: HY-132150A
CAS No.: 2375595-72-3
Purity:  98.69%
Target:  

MAP4K FLT3 Src

Research Areas:  

Cancer

HPK1-IN-2 dihydrochloride is an orally active HPK1 inhibitor (IC50 < 0.05 µM) with antitumor activity. HPK1-IN-2 dihydrochloride inhibits the activity of Lck (IC50 < 0.05 µM) and Flt3 (IC50 < 0.05 µM) kinases .
loading...
    loading...
Cat. No.: HY-P990046
CAS No.: 2649466-03-3
Synonyms: Incagn-02385

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology

Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .
loading...
    loading...
Cat. No.: HY-176203
Target:  

CD73

Research Areas:  

Cancer

XC-12 is an orally active and potent small-molecule CD73 inhibitor (an immune checkpoint) with IC50 values of 12.36 nM and 1.29 nM against soluble and membrane-bound CD73 forms, respectively. XC-12 is promising for research of cancers .
loading...
    loading...
Cat. No.: HY-P990031
CAS No.: 2649362-29-6
Synonyms: M-6223
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
loading...
    loading...
Cat. No.: HY-178756
Target:  

CDK

Research Areas:  

Cancer

CDK2-IN-48 (Compound 109) is a CDK2 inhibitor with IC50 values for CDK2 and CDK1 of respectively < 0.05 and > 1 μM. CDK2-IN-48 can be used for the study of CDK2-dependent cancers .
loading...
    loading...
Cat. No.: HY-153435
CAS No.: 2428422-17-5
Target:  

RIP kinase Necroptosis

Research Areas:  

Cancer

RIP1 kinase inhibitor 5 (example 1) is a potent inhibitor of RIP1, which is used as a checkpoint kinase to control tumor immunity . RIP1 kinase inhibitor 5 is similar with SIR1-365 (compound 13), which inhibits necrosis and iron death activity .
loading...
    loading...
Cat. No.: HY-149666
CAS No.: 2407854-31-1
Purity:  99.72%
Target:  

DGK

Research Areas:  

Cancer

BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC50of 0.09 (DGKα) and 0.006 μM (DGKζ) .
loading...
    loading...
Cat. No.: HY-169232
Target:  

PROTACs PD-1/PD-L1

Research Areas:  

Cancer

PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers .
loading...
    loading...
Cat. No.: HY-131187
CAS No.: 2447066-00-2
Purity:  97.18%
Research Areas:  

Cancer

BMS-1166-N-piperidine-COOH, the BMS-1166-based moiety, binds to E3 ligase ligand via a linker to form PROTAC PD-1/PD-L1 degrader-1 (HY-131183) to degrade PD-1/PD-L1 . BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .
loading...
    loading...
Cat. No.: HY-P990259
Anti-Mouse CD96 Antibody (3.3) is a rat-derived anti-mouse CD96 IgG1 λ type antibody inhibitor. Anti-Mouse CD96 Antibody (3.3) blocks binding of CD155 to CD96. Anti-Mouse CD96 Antibody (3.3) can enhance the antitumor efficacy of multiple immune-checkpoint inhibitors. Anti-Mouse CD96 Antibody (3.3) shows potent anti-tumor and anti-metastatic activity in various tumor models. Anti-Mouse CD96 Antibody (3.3) can be used for the researches of cancer and inflammation, such as mammary carcinoma .
loading...
    loading...
Cat. No.: HY-P11253
Target:  

VISTA

Research Areas:  

Inflammation/Immunology

DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a Kd value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [ 68Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy .
loading...
    loading...
Cat. No.: HY-P991181

Research Areas:  

Cancer

VTX-1218 is a VSIG4 inhibitor with human Kd 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types .
loading...
    loading...
Cat. No.: HY-175236
CAS No.: 3053768-78-5
SF-9-2 is a PD-L1/PD-1 binding inhibitor (IC50 = 24.9 nM). SF-9-2 inhibits epithelial-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells, and also induces apoptosis and cell cycle arrest. SF-9-2 blocks PD-L1-induced SK-N-SH cell growth through the MAPK signaling pathway. SF-9-2 restores GSK-3β activity and enhances PD-L1 degradation through the ubiquitin-proteasome pathway. SF-9-2 inhibits tumor growth in the SK-N-SH NOG mouse model without significant toxicity. SF-9-2 also acts as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function. SF-9-2 can be used in neuroblastoma research .
loading...
    loading...
Cat. No.: HY-131386
CAS No.: 2447066-14-8
Research Areas:  

Cancer

BMS-1166-N-piperidine-CO-N-piperazine incorporates a ligand for PD-1/PD-L1 immune checkpoint, and a PROTAC linker. BMS-1166-N-piperidine-CO-N-piperazine can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1?(HY-131183). PROTAC PD-1/PD-L1 degrader-1 inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM .
loading...
    loading...